Zyversa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome Asc Inhibitor Ic 100
Zyversa Therapeutics將肥胖症及相關代謝併發症選擇爲炎症小體ASC抑制劑IC100的主要指標。
Zyversa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome Asc Inhibitor Ic 100
Zyversa Therapeutics將肥胖症及相關代謝併發症選擇爲炎症小體ASC抑制劑IC100的主要指標。
譯文內容由第三人軟體翻譯。